Medgenics, Inc. (MDGN)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
5.73+0.06 (+1.06%)
At close: 4:01 PM EDT
People also watch:
CFRXMNOVFCSCMRTXSYN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5.76
Prev Close5.67
Bid5.73 x 300
Ask13.02 x 500
Day's Range5.69 - 5.85
52wk Range3.09 - 10.25
1y Target EstN/A
Market Cap212.46M
P/E Ratio (ttm)-3.86
Beta0.33
Volume13,759
Avg Vol (3m)143,074
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • MDGN: Several Upcoming Milestones Including NFC-1 ADHD Phase 2/3 Data
    Zacks Small Cap Research19 days ago

    MDGN: Several Upcoming Milestones Including NFC-1 ADHD Phase 2/3 Data

    Medgenics (MDGN) reported financial results for the second quarter ending June 30th and provided and operational update including status reports on their NFC-1 programs in ADHD and 22q Deletion Syndrome as well as their anti-LIGHT candidate targeting severe pediatric onset IBD. Q2 net loss and EPS were $11.7M and ($0.35), compared to our $11.4M and ($0.35) estimates.  Cash used in operating activities was $9.8M and $18.9M in the first three and six months of 2016.  Cash balance, bolstered by the June equity raise (3.8M shares @ $5.50/share) which netted ~$19.7M, was $53.7M at quarter end.  The sizeable raise and beefed-up cash balance allows development programs to remain on track and at their accelerated pace.  Management expects current cash to fund operations through Q1 2018.  By that time NFC-1 should have significant data points in both mGlurR+ ADHD and 22q and initial responder data should be available from the anti-LIGHT program.

  • Associated Press24 days ago

    Medgenics reports 2Q loss

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 35 cents. Medgenics shares have fallen slightly since the beginning of the year. The stock has dropped 23 percent in the ...

  • Marketwired24 days ago

    Medgenics Reports Second Quarter 2016 Financial Results

    Medgenics, Inc.